Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TSR-042 · 1 trial · 2 indications
Time from the date of randomization to the date of first documentation of disease progression or death due to any cause, whichever occurs first based on investigator assessment using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)
| Arm | Type | Description |
|---|---|---|
| No further treatment | EXPERIMENTAL | No further treatment |
| TSR-042 | EXPERIMENTAL | TSR-042 treatment administered using a 30 -minute IV infusion (with a -5 minute and +15 minute window permitted). |
| Name | Type | Description |
|---|---|---|
| No Further Treatment | OTHER | No further treatment |
| TSR-042 | DRUG | Fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for up to 24 months |
Inclusion Criteria: 1. Signed informed consent before any study-specific procedure 2. Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 3. Participant must be a female ≥ 18 years of age 4. Life expectancy ≥3 months 5. Participant must have biopsy-confirmed...
Top 20 of 27 competitors
TSR-042 is an investigational small molecule being studied as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation. It is currently in Phase 2 clinical development for this indication, with an active clinical trial evaluating its safety and efficacy in this patient population.
TSR-042 targets PD-1, a protein involved in immune checkpoint regulation. By targeting PD-1, TSR-042 is designed to modulate the immune system's response to cancer cells. This mechanism is being investigated in the context of cervical cancer, where it is being studied as a maintenance therapy following chemo-radiation.
TSR-042 is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. GSK is conducting clinical trials to evaluate TSR-042 as a potential treatment for cervical cancer, specifically as maintenance therapy for patients with high-risk locally advanced disease.
TSR-042 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 2 trial is evaluating TSR-042 as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation.
TSR-042 is being studied in a Phase 2 clinical trial with the identifier NCT03833479. This trial is titled 'TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation' and is actively recruiting participants. The trial is enrolling female patients aged 18 years and older in Spain and Turkey, with a target enrollment of 134 participants.
No, TSR-042 is not the same as dostarlimab. TSR-042 is a distinct investigational drug being developed by GSK plc for cervical cancer. While both drugs target PD-1, they are separate molecules with different chemical structures and are being evaluated in separate clinical trials.